Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma

BJU Int. 2014 Sep;114(3):334-9. doi: 10.1111/bju.12441. Epub 2013 Nov 27.

Abstract

Objective: To investigate the potential prognostic significance of the neutrophil-lymphocyte ratio (NLR) in a large European cohort of patients with upper urinary tract urothelial cell carcinoma (UUT-UCC).

Patients and methods: We retrospectively evaluated data from 202 consecutive patients with non-metastatic upper urinary tract urothelial cell carcinoma (UUT-UCC), who underwent surgery between 1990 and 2012 at a single tertiary academic centre. Patients' cancer-specific survival (CSS) and overall survival (OS) were assessed using the Kaplan-Meier method. To evaluate the independent prognostic significance of the NLR, multivariate proportional Cox regression models were applied for both endpoints.

Results: A higher NLR was significantly associated with shorter CSS (P = 0.002, log-rank test), as well as with shorter OS (P < 0.001, log-rank test). Multivariate analysis identified a high NLR as an independent prognostic factor for patients' CSS (hazard ratio 2.72, 95% CI 1.25-5.93, P = 0.012), and OS (hazard ratio 2.48, 95% CI 1.31-4.70, P = 0.005).

Conclusions: In the present cohort, patients with a high preoperative NLR had higher cancer-specific and overall mortality after radical surgery for UUT-UCC, compared with those with a low preoperative NLR. This easily identifiable laboratory measure should be considered as an additional prognostic factor in UUT-UCC in future.

Keywords: neutrophil-lymphocyte ratio; prognosis; upper tract urothelial carcinoma.

Publication types

  • Validation Study

MeSH terms

  • Biomarkers, Tumor / immunology
  • Carcinoma, Transitional Cell / immunology*
  • Carcinoma, Transitional Cell / mortality
  • Carcinoma, Transitional Cell / pathology
  • Disease Progression
  • Disease-Free Survival
  • Europe
  • Female
  • Humans
  • Inflammation / immunology*
  • Inflammation / pathology
  • Lymphocytes / immunology*
  • Male
  • Neutrophils / immunology*
  • Preoperative Care
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Ureteral Neoplasms / immunology*
  • Ureteral Neoplasms / mortality
  • Ureteral Neoplasms / pathology
  • Urothelium / pathology*

Substances

  • Biomarkers, Tumor